Top

International Journal of Clinical Pharmacy

Published in:

01-04-2010 | Case Report

Gastric ulcer in a child treated with deferasirox

Authors: Tiene Bauters, Veerle Mondelaers, Hugo Robays, Kathleen Hunninck, Barbara de Moerloose

Published in: International Journal of Clinical Pharmacy | Issue 2/2010

Abstract

We present a patient with thalassemia major who developed a gastric ulcer, probably related to the use of deferasirox. Although gastric ulcer is mentioned as infrequent adverse event in the scientific product information of deferasirox, in our current knowledge, this is the first case-report on this adverse drug reaction. The severity of this event justifies the reporting of this case.

Stumpf J. Deferasirox. Am J Health Syst Pharm. 2007;64:606–16.CrossRefPubMed

Cappellini M. Long-term efficacy and safety of deferasirox. Blood Rev. 2008;22(S2):S35–41.CrossRefPubMed

Raphael JL, Bernhardt MB, Mahoney DH, Mueller BU. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer. 2009;52(5):616–20.CrossRefPubMed

Vanorden HE, Hagemann TM. Deferasirox. An oral agent for chronic iron overload. Ann Pharmacother. 2006;40(6):1110–7.CrossRefPubMed

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–62.

Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006;91(10):1343–51.PubMed

Scientific Leaflet Deferasirox (in Flemish). http://www.ecompendium.be/. Accessed 3 August 2009.

Scientific Leaflet Folic Acid (in Flemish). http://www.ecompendium.be/. Accessed 3 August 2009.

Identifying Adverse Drug Reactions. http://mqa.dhs.state.tx.us/QMWeb/MedSim/Naranjo.htm. Accessed 14 April 2009.

10.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.CrossRefPubMed

Title: Gastric ulcer in a child treated with deferasirox
Authors: Tiene Bauters
Veerle Mondelaers
Hugo Robays
Kathleen Hunninck
Barbara de Moerloose
Publication date: 01-04-2010
Publisher: Springer Netherlands
Published in: International Journal of Clinical Pharmacy / Issue 2/2010
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-009-9357-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gastric ulcer in a child treated with deferasirox

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Are local clinical guidelines useful in promoting rational use of antibiotic prophylaxis in Caesarean delivery?

Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database

A pilot study to compare natural health product–drug interactions in two databases in Canada

“It’s just routine.” A qualitative study of medicine-taking amongst older people in New Zealand

Severe ifosfamide-induced neurotoxicity: a case report

Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after treatment with infliximab

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page